β 受体阻滞剂是一类常用于控制血压的药物，一直是有关其与前列腺癌 (PC) 风险、预后和治疗关系的研究主题。 β-受体阻滞剂可降低 PC 风险并改善预后。围手术期使用非选择性β受体阻滞剂可改善根治性前列腺切除术后的预后。然而，一类相关的药物，β-2 肾上腺素能激动剂，在 PC 治疗中却很少受到关注。我们研究了 β-2 肾上腺素能激动剂沙丁胺醇与 PC 风险和生存的关系。我们分析了美国食品和药物管理局 MedWatch 数据，以确定沙丁胺醇是否会影响 PC 风险。我们使用英国生物银行数据来评估沙丁胺醇对 PC 生存的影响。沙丁胺醇显着降低 PC 风险、比例报告比和 95% CI（下限；上限）：0.131（0.11；0.155）并改善预后。不服用沙丁胺醇的受试者的平均生存期为 7.35 年，服用沙丁胺醇的受试者的平均生存期为 10.5 年（P = 0.041，对数秩检验。为了调整年龄的影响，我们进行了比例风险回归、生存时间依赖变量、年龄、沙丁胺醇的使用与生存时间显着相关（P = 0.016），且与年龄的显着影响无关（P < 0.001）。我们发现沙丁胺醇治疗人群中 PC 的比例较低，但我们尚未发现。表明 PC 风险降低（没有因果关系证据）。与未接受该药物治疗的 PC 患者相比，沙丁胺醇与 PC 患者的生存率之间没有因果关系。因此，沙丁胺醇和其他 β-肾上腺素能激动剂可能代表一类新的 PC 治疗药物。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

Beta-blockers, a class of drugs commonly used to manage blood pressure, have been the subject of research regarding their relationship to prostate cancer (PC) risk, prognosis, and treatment. Beta-blockers reduce risk and improve the prognosis of PC. Perioperative use of a nonselective beta-blocker improves outcomes after radical prostatectomy. However, a related class of drugs, beta-2 adrenergic agonists, has received little attention in PC.We studied the relationship of the beta-2 adrenergic agonist salbutamol to PC risk and survival. We analyzed Food and Drug Administration MedWatch data to determine whether salbutamol could influence the risk of PC. We used UK Biobank data to assess the effect of salbutamol on PC survival.Salbutamol significantly reduces PC risk, proportional reporting ratio, and 95% CI (lower bound; upper bound): 0.131 (0.11; 0.155) and improves prognosis. Mean survival was 7.35 years for subjects not taking salbutamol, and 10.5 years for subjects taking salbutamol (P = 0.041, log-rank test. To adjust for the effect of age, we performed proportional hazards regression, survival time-dependent variable, age, and salbutamol use independent variables. Salbutamol use was significantly related to survival time (P = 0.016) and independent of the significant effect of age (P < 0.001).We found a lower proportion of PCs in salbutamol-treated people, but we have not demonstrated that PC risk is reduced (there is no proof of causality). There is no causality relationship between salbutamol and the survival of patients with PC treated with salbutamol versus those not treated with the drug. Yet, there is a trend in favor of salbutamol-treated patient survival. Therefore, salbutamol and other beta-adrenergic agonists might represent a new class of drugs for the treatment of PC.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.